Your session is about to expire
← Back to Search
Immunotherapy + Chemotherapy with Stem Cell Transplant for Multiple Myeloma
Study Summary
This trial is testing a combination of immunotherapy and chemotherapy before stem cell transplant to treat multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to thalidomide or lenalidomide, or have had a severe skin rash from taking them before.I have high-risk multiple myeloma and am eligible for a transplant, with my condition at least partially improved.My heart pumps well, with an ejection fraction over 40%.I agree to use a condom during sex if my partner can have children, even though I've had a vasectomy.I have a cord blood unit that matches my HLA markers.I can take care of myself and perform daily activities without help.I do not have any uncontrolled illnesses that could affect my participation.My kidneys are functioning well, with a creatinine clearance rate of at least 60 ml/min.I agree to follow the pregnancy testing schedule as required.Your lung test shows that your ability to transfer oxygen is at least 40% of what is expected for someone your age and size.I have plasma cell leukemia and am eligible for a transplant.Your bilirubin levels are within a certain range.You have had allergic reactions to drugs similar to melphalan.I do not have HIV.Your SGPT level in the blood is less than 3 times the normal limit.
- Group 1: Treatment (chemotherapy, UCB-derived NK cells, transplant)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
At what age are patients eligible for this research study?
"This particular study only allows patients aged 18-75 to enroll. There are 64 other clinical trials available for people under the age of 18 and 1154 for those over 65."
Are there any open vacancies for this clinical research program?
"This study is no longer looking for new participants. The trial began on June 10th, 2013 and ended on August 18th, 2022. There are currently 840 other clinical trials related to neoplasms, plasma cell seeking patients and 343 trials involving Elotuzumab that are open for enrollment."
How is Elotuzumab used to help patients?
"Elotuzumab is a potential treatment for stage i mycosis fungoides, polycythemia vera (pv), and patients that have undergone two or more rounds of systemic chemotherapy."
How many people can join this trial at most?
"Unfortunately, this particular study is no longer looking for participants. The trial was initially posted on 6/10/2013 and ended recruitment on 8/18/2022. However, there are presently 840 clinical trials actively searching for participants with neoplasms and plasma cell. Additionally, 343 trials for Elotuzumab are also recruiting patients."
Has Elotuzumab been given the green light by the FDA?
"Since this is a Phase 2 trial, meaning that while there is some evidence to support safety, there is none for efficacy, we have given Elotuzumab a score of 2."
How do I go about signing up for this clinical trial?
"This study is only considering patients that have neoplasms, plasma cell and are between 18-75 years old. They will be looking to accept a total of 72 people into the trial."
Share this study with friends
Copy Link
Messenger